High Growth Tech Stocks To Watch In November 2024

In This Article:

As global markets react to the evolving policy landscape under the new Trump administration, with significant movements across sectors like financials and energy, investors are closely watching how these changes impact corporate earnings and market sentiment. In this dynamic environment, identifying high-growth tech stocks requires a focus on companies that can adapt to regulatory shifts and leverage technological advancements to maintain robust growth trajectories.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Material Group

20.45%

24.01%

★★★★★★

Yggdrazil Group

24.66%

85.53%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Seojin SystemLtd

33.54%

52.43%

★★★★★★

Medley

25.57%

31.67%

★★★★★★

Pharma Mar

26.94%

56.39%

★★★★★★

Mental Health TechnologiesLtd

27.88%

79.61%

★★★★★★

Elliptic Laboratories

65.73%

103.55%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

UTI

114.97%

134.60%

★★★★★★

Click here to see the full list of 1297 stocks from our High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

SK bioscienceLtd

Simply Wall St Growth Rating: ★★★★★☆

Overview: SK bioscience Co., Ltd. focuses on the research, development, production, and distribution of vaccines and biopharmaceuticals both in Korea and internationally, with a market cap of ₩3.89 trillion.

Operations: SK bioscience generates revenue primarily through the sale of vaccines and biopharmaceutical products. The company is involved in both domestic and international markets, focusing on research, development, production, and distribution activities within these sectors.

SK bioscience, amid challenging market conditions, is navigating with promising forecasts and strategic approvals. The company's revenue is expected to surge by 22.2% annually, outpacing the KR market's growth of 9.5%. This growth trajectory is bolstered by the recent approval in Indonesia for SKYCellflu, a significant advancement as it represents the world’s first quadrivalent cell-cultured influenza vaccine. Furthermore, earnings are projected to grow at an impressive rate of 70.9% per year. Despite current unprofitability and shareholder dilution over the past year, these developments could position SK bioscience favorably in high-demand markets, especially given its pioneering status in cell-cultured vaccine technology which offers faster production times and potentially more effective responses to pandemics compared to traditional methods.